FDA Issues Complete Response Letter for Ivonescimab in EGFR-Mutated NSCLC After TKI Therapy

On November 15, 2026, Summit Therapeutics announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the biologics license application (BLA) for ivonescimab plus platinum-containing chemotherapy. The application cannot be approved in its present form. Ivonescimab is a PD-1 × VEGF bispecific antibody invented by Akeso (HKEX: 09926); Summit holds rights in the United States and other licensed territories. The sought indication is locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy.
Timeline
- May 2024: Ivonescimab received its first marketing authorization in China.
- January 29, 2026: The FDA accepted the BLA for filing and assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 14, 2026.
- November 15, 2026 (Sunday): Summit announced receipt of the CRL, one day after the PDUFA goal date. The company did not provide a resubmission timeline in that announcement.
Key facts
The BLA was supported by HARMONi, a global, randomized, double-blind Phase 3 trial comparing ivonescimab plus platinum-containing chemotherapy with placebo plus platinum-containing chemotherapy. The trial enrolled patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC previously treated with a third-generation EGFR TKI. The study had two primary endpoints: progression-free survival (PFS) and overall survival (OS).
The trial met its PFS primary endpoint. Median PFS, assessed by an independent radiographic review committee, was 6.8 months with ivonescimab plus chemotherapy versus 4.4 months with placebo plus chemotherapy, with a hazard ratio (HR) of 0.52 (95% CI 0.41–0.66; p<0.0001). Summit said HARMONi was the first global Phase 3 study of an immunotherapy-based regimen to show a statistically significant PFS improvement in this setting.
The primary OS analysis did not reach statistical significance. That analysis, performed in April 2025, showed a positive trend: HR 0.79 (95% CI 0.62–1.01; p=0.057), with median OS of 16.8 months versus 14.0 months. In a later analysis with a June 2026 data cutoff, after longer follow-up of Western patients, Summit reported an OS HR of 0.76 in the global intention-to-treat population (95% CI 0.61–0.95; nominal p=0.0151). The company also reported an HR of 0.76 in both the Asian and Western subgroups; the Western subgroup confidence interval was 0.52–1.10 and crossed 1. This updated analysis was post hoc and was not the primary OS analysis.
According to Summit’s account of the CRL, the FDA determined that substantial evidence of effectiveness is not established in the absence of a statistically significant OS improvement, and that a PFS benefit without a statistically significant OS benefit does not support a positive benefit-risk profile for approval. Summit also stated that no FDA-approved regimen has demonstrated a statistically significant OS benefit in this patient setting.
On safety, Summit’s November 15 release said ivonescimab plus chemotherapy had an acceptable and manageable safety profile consistent with previous studies, with no new safety signals. Treatment-related adverse events led to discontinuation in 16 patients (7.3%) on ivonescimab and 11 patients (5.0%) on placebo, and to death in four patients (1.8%) and five patients (2.3%), respectively.
Robert W. Duggan, chairman and co-chief executive officer of Summit, said the company was disappointed for patients and families awaiting additional options in this setting, and that five positive Phase 3 studies between Summit and Akeso had not changed the company’s determination to advance ivonescimab. The release listed ongoing development in first-line metastatic NSCLC (HARMONi-3 and HARMONi-7), as well as programs in colorectal cancer, urothelial carcinoma, and renal cell carcinoma. Ivonescimab remains an investigational therapy in Summit’s licensed territories, including the United States and Europe. No PD-1 × VEGF bispecific antibody is currently approved in the United States. As of this draft, a standalone official Akeso press release on the CRL had not been located; Chinese-language coverage has relied primarily on Summit’s announcement.
The announcement was made on a Sunday, when U.S. regular-session trading was closed. The regular-session reaction in Summit shares (Nasdaq: SMMT) had not yet been established at the time of writing. In Hong Kong trading on November 16, Akeso shares fell sharply. Yicai reported that as of 9:40 a.m. that morning, the stock was still down about 23.03%, with the company’s market value below HK$60 billion. Those figures are intra-day, not a closing print.
Significance
The decision delays the first potential U.S. approval of a PD-1 × VEGF bispecific antibody and makes clear that, in this setting, the FDA required a statistically significant OS benefit and did not accept a PFS win, or a non-significant or post-hoc survival trend, as sufficient for approval.
Sources
- Summit Therapeutics press release, November 15, 2026: https://www.smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx
- Summit Therapeutics press release (BLA acceptance and PDUFA date), January 29, 2026: press release
- Summit Therapeutics press release (HARMONi primary analysis in The Lancet Oncology; PFS results), August 25, 2026: press release
- Summit Therapeutics press release (updated OS analysis at WCLC 2026), for the primary and June 2026 OS figures: press release
- Reuters, November 15, 2026 (via syndicate reprints): FDA cited the lack of a statistically significant overall-survival improvement in issuing the CRL
- Yicai, November 16, 2026: https://www.yicai.com/news/103441396.html (Hong Kong intra-day move as of 9:40 a.m.)
This item summarizes public disclosures and is not investment advice.
Commentary · Rocky
This was not a safety event, and the data were not overturned: progression-free survival was met, while the primary overall-survival analysis (HR 0.79, p=0.057) missed its pre-specified statistical threshold; a later, post-hoc update to 0.76 — with the Western subgroup confidence interval still crossing 1 — does not replace the overall-survival benefit the review required. The complete response letter delays the first potential U.S. approval of a PD-1 × VEGF bispecific, but it assesses a relatively narrow, later-line setting; it should not be written as a turning point for China-originated assets seeking U.S. approval, nor as a verdict on this mechanism in first-line therapy. A closer reading is less dramatic: in an indication where the agency had already made clear that it would look to overall survival, submitting on a primary analysis that did not reach significance was a calculable risk, not a surprise after the fact. The ticket is still there; it has simply become more expensive.
— Rocky
This comment is the author’s view, not that of InLight Editorial, and is not investment advice.